Abstract 26P
Background
Subcutaneous (SC) trastuzumab offers a distinctive approach to treat HER2-positive breast cancer in contrast with conventional intravenous (IV) infusion. SC can be administered at day care unit, which is potentially a big step forward with a more efficient treatment mode compared to IV administration at inpatient wards. This study aimed to quantify the impact of treatment mode transition by measuring its benefits to hospitals as well as patients in China.
Methods
This time-motion study was conducted in Tianjin Medical University Cancer Institute & Hospital, where breast cancer treatment mode was shifted from IV administration at inpatient ward to SC administration at day care unit. The duration of each specific task conducted by HCPs and the time patient spent were recorded by observers. Costs, including HCP salaries, medical consumables, and other relevant items, were collected from public sources. The study outcomes included hospital capacity improvements, time savings for HCPs, and cost reductions for hospital. Meanwhile, patients' time savings and cost of lost labor were also measured.
Results
The treatment mode transition significantly improved the hospital operation efficiency. For 80 patients visited per day, IV administration required 80 inpatient beds, but SC administration in day care unit only occupied 6 injection chairs, equals to a freeing up of around 24,960 bed-days annually for a hospital. Considering this optimized and reallocated inpatient resources, estimated potential benefits were CNY 68,902 per day and CNY 21,497,490 per year. In addition, the adoption of SC administration reduced nursing working hour by 81%. For patients and caregivers, the treatment time per cycle was 91% less than IV administrations, leading to total savings of CNY 19,681 per patient in terms of direct cost and productivity cost over a full course of treatment.
Conclusions
Besides saving time for HCPs and patients, trastuzumab SC can help optimize treatment process, improve overall quality and efficiency of healthcare system & hospital management, aligned with China policies of high-quality hospital development.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tianjin Medical University Cancer Institute & Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract